Lead Product(s) : KJ-C2219
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CARsgen Doses First Patient in CD19/CD20 CAR-T Autoimmune Disease Trial
Details : KJ-C2219 is an allogeneic CAR-T therapy targeting CD19/CD20, has administered at the starting dose specified in the clinical protocol to the first patient with SLE.
Product Name : KJ-C2219
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : KJ-C2219
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AC-101
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
Details : AC-101 is a novel RIPK2 inhibitor, small molecule drug candidate, which is being developed for the treatment of moderate-to-severe ulcerative colitis.
Product Name : AC-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 13, 2025
Lead Product(s) : AC-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GC012F
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gracell lead candidate BCMA/CD19 dual-targeting inhibitor FasTCAR-T GC012F is currently being evaluated in Phase I clinical trial studies for the treatment of refractory Systemic Lupus Erythematosus.
Product Name : GC012F
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : GC012F
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relmacabtagene Autoleucel
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Relma-cel (relmacabtagene autoleucel) is based on the same chimeric antigen receptor (CAR) construct, currently beinf investigated in patients with moderately or severely refractory systemic lupus erythematosus.
Product Name : Carteyva
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Relmacabtagene Autoleucel
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : T21
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : T21 is Triastek’s third 3D printed oral colon-targeted delivery drug product, and is an oral, colon-targeted delivery drug for moderate to severe ulcerative colitis (UC).
Product Name : T21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : T21
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MHB018A
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MHB018A is a novel fusion protein of humanized single domain IGF-1R antibody and human Fc, which showed 3~5 times greater ligand blocking activities than other known IGF-1R antibodies for both IGF-1 and IGF-2.
Product Name : MHB018A
Product Type : Protein
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : MHB018A
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MHB018A
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MHB018A is a novel fusion protein of humanized single domain IGF-1R antibody and human Fc, which showed 3~5 times greater ligand blocking activities than other known IGF-1R antibodies for both IGF-1 and IGF-2.
Product Name : MHB018A
Product Type : Protein
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : MHB018A
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GC012F
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : RenJi Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GC012F is a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T product candidate, currently being evaluated for treatment of refractory systemic lupus erythematosus (SLE).
Product Name : GC012F
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : GC012F
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : RenJi Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LNK01003
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
Details : LNK01003 is an oral small molecule JAK inhibitor with intestine-restricted properties developed by the company for the treatment of ulcerative colitis and related diseases.
Product Name : LNK01003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2023
Lead Product(s) : LNK01003
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IBI311
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)
Details : IBI311 is a monoclonal antibody targeting IGF-1R developed by Innovent for the treatment of active TAO. By blocking the binding of IGF-1 and IGF-2 to IGF-1R, IBI311 inhibits IGF-1R signaling pathway activation and reduces the expression of downstream inf...
Product Name : IBI311
Product Type : Antibody
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : IBI311
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable